Trials / Not Yet Recruiting
Not Yet RecruitingNCT07110363
A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer
An Open-label Phase Ib Study on the Safety, Tolerability, and Efficacy of BT02 in Treating Patients With Advanced Lung Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 58 (estimated)
- Sponsor
- Biotroy Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to assess whether an investigational treatment is safe and tolerable for patients with advanced lung cancer, and to get a preliminary idea of its effectiveness. Participants of all genders, aged between 18 and 75(inclusive), are eligible to join. These patients will receive the investigational drug intravenously every two weeks. If their condition doesn't worsen and they don't experience unbearable side effects, they can continue the treatment for up to two years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BT02 | monoclonal antibody injection with intravenous administration every 2 or 3 weeks |
Timeline
- Start date
- 2025-08-01
- Primary completion
- 2027-03-01
- Completion
- 2027-05-01
- First posted
- 2025-08-07
- Last updated
- 2025-08-07
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07110363. Inclusion in this directory is not an endorsement.